These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23914773)

  • 1. Local therapies for inflammatory eye disease in translation: past, present and future.
    Tempest-Roe S; Joshi L; Dick AD; Taylor SR
    BMC Ophthalmol; 2013 Aug; 13(1):39. PubMed ID: 23914773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.
    Gallego-Pinazo R; Dolz-Marco R; Martínez-Castillo S; Arévalo JF; Díaz-Llopis M
    Inflamm Allergy Drug Targets; 2013 Feb; 12(1):38-45. PubMed ID: 23441991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in corticosteroid therapy for uveitis.
    Taylor SR; Isa H; Joshi L; Lightman S
    Ophthalmologica; 2010; 224 Suppl 1():46-53. PubMed ID: 20714181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update in treatment of uveitic macular edema.
    Koronis S; Stavrakas P; Balidis M; Kozeis N; Tranos PG
    Drug Des Devel Ther; 2019; 13():667-680. PubMed ID: 30858697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapies for inflammatory eye disease: past, present and future.
    Denniston AK; Dick AD
    BMC Ophthalmol; 2013 Apr; 13():18. PubMed ID: 23617902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview and recent developments in the medical management of paediatric uveitis.
    Pilly B; Heath G; Tschuor P; Lightman S; Gale RP
    Expert Opin Pharmacother; 2013 Sep; 14(13):1787-95. PubMed ID: 23826652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.
    Gaballa SA; Kompella UB; Elgarhy O; Alqahtani AM; Pierscionek B; Alany RG; Abdelkader H
    Drug Deliv Transl Res; 2021 Jun; 11(3):866-893. PubMed ID: 32901367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Road to remission: a comprehensive review of therapy in uveitis.
    Siddique SS; Shah R; Suelves AM; Foster CS
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1497-515. PubMed ID: 21936708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Refractory anterior uveitis].
    Labalette P
    J Fr Ophtalmol; 2011 Feb; 34(2):122-6. PubMed ID: 21236513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the treatment of noninfectious uveitis.
    Pleyer U; Pohlmann D; Kardeş E; Poddubnyy D; Rademacher J
    Expert Opin Emerg Drugs; 2019 Sep; 24(3):173-190. PubMed ID: 31498689
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of chronic non-infectious uveitis and scleritis.
    Rossi DC; Ribi C; Guex-Crosier Y
    Swiss Med Wkly; 2019 Feb; 149():w20025. PubMed ID: 30852832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
    Zlatanović G; Jovanović S; Veselinović D; Zivković M
    Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveitis Therapy: The Corticosteroid Options.
    Valdes LM; Sobrin L
    Drugs; 2020 Jun; 80(8):765-773. PubMed ID: 32350761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Corticosteroids and ophthalmology].
    Girard B
    Rev Prat; 1990 Feb; 40(6):536-40. PubMed ID: 2320879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.